Acute Respiratory DiseasesNCT07899749
Fermented Mare's Milk Supplementation During Acute Viral Respiratory Infection
A study testing Fermented mare's milk in people with Acute Respiratory Diseases, run by Khoja Akhmet Yassawi International Kazakh-Turkish University.
Trial summary
Fermented mare's milk contains proteins, small protein fragments, and beneficial microbes that may influence the immune system. This study will examine whether drinking fermented mare's milk can change blood levels of substances that control inflammation and improve symptoms and recovery in adults with a short-term… Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Acute Respiratory Diseases
- What is being tested?
- Fermented mare's milk
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 400 participants
- Where
- No sites listed yet
- Study dates
- 30 Oct 2026to 30 Oct 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Patients with acute respiratory diseases
Who cannot join
- All Other diseases
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Fermented Mare's Milk Supplementation Modulates Inflammatory and Regulatory Cytokine Responses During Acute Viral Respiratory Infection: a Randomized Controlled Multicenter Study
Fermented mare's milk contains proteins, small protein fragments, and beneficial microbes that may influence the immune system. This study will examine whether drinking fermented mare's milk can change blood levels of substances that control inflammation and improve symptoms and recovery in adults with a short-term viral respiratory infection.
- Conditions
- Acute Respiratory Diseases
- Being tested
- Fermented mare's milk
- Keywords
- Acute respiratory diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fermented mare's milkDietary supplement
Fermented mare's milk beverage will be administered orally at a total daily volume of 200 mL for seven consecutive days, in addition to standard care. This intervention will be provided only to participants assigned to the experimental arm.
| Study group | Role | What they receive |
|---|---|---|
| Fermented mare's milk plus standard care | Experimental | Participants will receive fermented mare's milk orally at a total daily volume of 200 mL for seven consecutive days, in addition to standard care for acute viral respiratory infection. Receives: Dietary Supplement: Fermented mare's milk |
| Standard care alone | Active comparator | Participants will receive standard care for acute viral respiratory infection during the seven-day intervention period. They will not receive fermented mare's milk or a placebo. Receives: Dietary Supplement: Fermented mare's milk |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in blood levels of inflammatory and immune-regulating cytokines (IL-6, TNF-α, IL-10, and TGF-β) from baseline to Day 7, comparing fermented mare's milk plus standard care with standard care alone.
Measured: Baseline (before starting treatment) and Day 7.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Oct 2026
- Study start30 Oct 2026 (estimated)
- Primary completion30 Sep 2027 (estimated)
- Study completion30 Oct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Acute Respiratory DiseasesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 400 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Khoja Akhmet Yassawi International Kazakh-Turkish University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ylham Annaorazov, Khoja Akhmet Yassawi International Kazakh-Turkish University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07899749
- Sponsor's protocol ID
- Protocol 41
- Status last verified
- Oct 2026
- First submitted
- 20 Oct 2026
- Last updated
- 27 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Fermented Mare's Milk Supplementation Modulates Inflammatory and Regulatory Cytokine Responses During Acute Viral Respiratory Infection: a Randomized Controlled Multicenter Study
- ClinicalTrials.gov ID
- NCT07899749
- Acronym / sponsor ID
- Protocol 41
- Conditions
- Acute Respiratory Diseases
- Keywords
- Acute respiratory diseases
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 400 participants (estimated)
- Lead sponsor
- Khoja Akhmet Yassawi International Kazakh-Turkish UniversityUniversity, hospital or other
- Study start
- 30 Oct 2026 (estimated)
- Primary completion
- 30 Sep 2027 (estimated)
- Study completion
- 30 Oct 2027 (estimated)
- First posted
- 27 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Fermented mare's milk contains proteins, small protein fragments, and beneficial microbes that may influence the immune system. This study will examine whether drinking fermented mare's milk can change blood levels of substances that control inflammation and improve symptoms and recovery in adults with a short-term viral respiratory infection.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Fermented mare's milk plus standard care | Experimental | Dietary Supplement: Fermented mare's milkParticipants will receive fermented mare's milk orally at a total daily volume of 200 mL for seven consecutive days, in addition to standard care for acute viral respiratory infection. |
| Standard care alone | Active comparator | Dietary Supplement: Fermented mare's milkParticipants will receive standard care for acute viral respiratory infection during the seven-day intervention period. They will not receive fermented mare's milk or a placebo. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients with acute respiratory diseases
Key exclusion criteria (1 listed)
- All Other diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fermented mare's milkFermented mare's milk beverage will be administered orally at a total daily volume of 200 mL for seven consecutive days, in addition to standard care. This intervention will be provided only to participants assigned to the experimental arm. | Dietary supplement | Fermented mare's milk plus standard care, Standard care alone |
Primary outcome
Change in blood levels of inflammatory and immune-regulating cytokines (IL-6, TNF-α, IL-10, and TGF-β) from baseline to Day 7, comparing fermented mare's milk plus standard care with standard care alone.
Time frame: Baseline (before starting treatment) and Day 7.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Acute Respiratory Diseases
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Active, not recruiting
CT for Personalized Mechanical Ventilation
Ventilator-Induced Lung Injury, Sepsis Syndrome
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
Not yet recruitingObservational study
Development and Multicenter Validation of an Explainable System for Neonatal ARDS-Compatible Phenotyping
Acute Respiratory Distress Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Fermented mare's milk in people with Acute Respiratory Diseases, run by Khoja Akhmet Yassawi International Kazakh-Turkish University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Zhanna Rakhimbayeva (+7 702 640 7281, dr.zhanna.80@mail.ru), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in blood levels of inflammatory and immune-regulating cytokines (IL-6, TNF-α, IL-10, and TGF-β) from baseline to Day 7, comparing fermented mare's milk plus standard care with standard care alone. (time frame: Baseline (before starting treatment) and Day 7.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.